News
Verona Pharma launches late-stage COPD trial programme
Verona Pharma has initiated phase III trials to evaluate the safety and efficacy of nebulised ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Verona Pharma has initiated phase III trials to evaluate the safety and efficacy of nebulised ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).